<DOC>
	<DOC>NCT02216409</DOC>
	<brief_summary>The purpose of this study is to assess the safety and tolerability of Hu5F9-G4 in participants with solid tumors.</brief_summary>
	<brief_title>Phase 1 Trial of Hu5F9-G4, a CD47-targeting Antibody</brief_title>
	<detailed_description>This is a first-in-human, first-in-class, escalating dose trial of an antibody that inhibits an anti-apoptotic signal in human macrophages. The major aims of the study are to define the safety profile of this new drug, and to determine a recommended dose and schedule for potential additional trials.</detailed_description>
	<criteria>Patients with histologically or cytologically confirmed advanced solid malignancy or Lymphoma Relapsed or refractory disease after at least 1 prior systemic treatment for the primary malignancy and not a candidate for other curative treatment. Adequate hematologic status Adequate coagulation function Adequate hepatic function Adequate renal function Known primary tumors of central nervous system disease Known active brain metastases Known cardiopulmonary disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>